Dendreon busts out of biotech with capacity boost

Dendreon say all three of its manufacturing plants should be online and shipping its prostate cancer vaccine by year's end. Provenge is the first vaccine approved for cancer treatment. The manufacturing ramp-up makes Dendreon "a biotech that's become a commercial company now," says Needham & Co. analyst Mark Monane. Sales of the drug were stymied by production constraints. But expansion at a New Jersey plant and  pending regulatory approvals for plants in California and Georgia should eliminate the problem. Story

Suggested Articles

Colorado is making a play for a Japanese CDMO in hopes it will invest about $100 million in an empty AstraZeneca plant in Boulder.

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.